Parallax Volatility Advisers
LAB icon

Parallax Volatility Advisers’s Standard BioTools LAB Stock Holding History

Parallax Volatility Advisers’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-100
Closed -$1K – 2127
2021
Q3 		$1K Buy
+100
New +$658 ﹤0.01% 1975

Other funds holding LAB

ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parallax Volatility Advisers's LAB Position: Q2 2019 in Review

Parallax Volatility Advisers sold out of Standard BioTools (LAB) in Q2 2019, closing a stake of 9,200 shares — an estimated $122K sold.

Parallax Volatility Advisers first reported a position in LAB in Q4 2017 and held it in 2 quarters. The position peaked at $122K in Q1 2019. 135 funds tracked by Wall St. Rank hold LAB as of Q2 2019.

  • Parallax Volatility Advisers reported no remaining Standard BioTools position as of Q2 2019 after selling out during the quarter.
  • Parallax Volatility Advisers sold 9,200 Standard BioTools shares in Q2 2019, an estimated $122K.
  • Parallax Volatility Advisers first reported a position in Standard BioTools in Q4 2017 and held it in 2 quarters.
  • Parallax Volatility Advisers's Standard BioTools position peaked at $122K in Q1 2019.
  • 135 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2019.

Based on Parallax Volatility Advisers's 13F filing for Q2 2019, filed 14 Aug 2019.